Clinical considerations of lipid target and goal in dyslipidemia control  by Wu, Na-Qiong & Li, Jian-Jun
Available online at www.sciencedirect.comScienceDirect
Chronic Diseases and Translational Medicine 2 (2016) 3e6
www.keaipublishing.com/en/journals/cdtm/Perspective
Clinical considerations of lipid target and goal in dyslipidemia
control
Na-Qiong Wu, Jian-Jun Li*
Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases,
Chinese Academy of Medical Sciences, Beijing 100034, China
Received 11 May 2016
Available online 28 June 2016
www.cdatm.orgIn clinical practice, physicians often use certain
strategies based on guidelines or recommendations
from experts. This is because in the era of evidence-
based medicine, clinicians are more willing to make
“evidence-based” decisions. This is also the case in the
field of lipid-lowering therapy. The term “lipid-
lowering therapy” does not simply refer to items with
abnormal values in the lipid profile, and individualized
management is all the more important in the overall
assessment of a patient. Thus, it is easy to conclude
that doctors need a relatively authoritative assessment
system to determine whether a patient requires lipid-
lowering therapy, as well as the intensity of therapy,
the blood lipid indicators for therapy, and the expected
target of therapy. The above-mentioned issues are
briefly reviewed in this paper.
Definitions of “target” and “target goal” in lipid
management
Clinical routine lipid screening includes screening
for total cholesterol (TC), triglyceride (TG), high-
density lipoprotein cholesterol (HDL-C), and low-
density lipoprotein cholesterol (LDL-C). Such* Corresponding author. Tel.: þ86 10 88396584.
E-mail address: lijianjun938@126.com (J.-J. Li).
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profile for the prevention and treatment of cardiovas-
cular diseases.
Gradual progress in the study of the relationship
between cholesterol and cardiovascular disease (CVD)
and the gradual accumulation of clinical evidence have
enabled a better understanding of the importance of all
lipid components in the pathogenesis of CVD, and the
concepts of “target” and “target goal” have been
generated. Therefore, in recent years, LDL-C and non-
HDL cholesterol (non-HDL-C) have been identified as
the “targets” in the guidelines for lipid management,
and apolipoprotein B (ApoB) is the secondary target in
some guidelines.1e3
For the corresponding targets, different “target
goals” are defined in most guidelines according to the
levels of risk, to guide the lipid management in
different groups and to minimize the risk of cardio-
vascular events on a scientific basis.
Recommendations for the stratification of “target”
and “target goal” in international and domestic
lipid guidelines
In 1988 and 1993, when the US National Cholesterol
Education Program (NCEP) Adult Treatment Panel I
(ATP I) was developed and the ATP II was updated, the
evidence-based clinical information for lipid manage-
ment, especially for the use of statin drugs in cholesterol-
lowering therapy, was not sufficient.4,5 At that time, the
harmful effect of hypercholesterolemia on cardiovascularElsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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II recommended the use of LDL-C as the primary target
for intervention. The development and updates of the
guidelines were mostly based on epidemiological evi-
dence or the evidence from statin studies. The risk strat-
ification of target populations for lipid management was
emphasized in the European lipid management guide-
lines (hereinafter referred to as “European guideline”)1
jointly issued for the first time by the European Society
of Cardiology (ESC) and European Atherosclerosis So-
ciety (EAS) in 2011, and in the patient-centered man-
agement of dyslipidemia released by the National Lipid
Association (NLA) in 2014 (hereinafter referred as “the
latest US recommendation”). Additionally, very high,
high, moderate, and low atherosclerotic risk were strati-
fied.3 Among various guidelines, there are some differ-
ences in the definitions of the above-mentioned risk
stratifications. Among these, the representative European
guideline proposed the SCORE rating scale. In the 2013
US lipid guideline, an expert team developed assessment
tools for adult cardiovascular disease risk, in order to
conduct quantitative assessment in patients.2 The expert
team developed a new cardiovascular risk scoring system
using a large number of research data based on different
ethnic backgrounds and in different areas, including the
Framingham Heart Study (FHS), the Atherosclerosis
Risk in Community Study (ARIC), the Coronary Artery
Risk Development in Young Adults Study (CARDIA),
and the Cardiovascular Health Study (CHS). The risk
assessment equation can predict the risks of CVD and
stroke.
Compared with the NCEPATP III and the 2007 Chi-
nese lipid guidelines,6,7 the European guideline has a
broader definition of very high-risk groups, and LDL-C
treatment target is more stringent. In NCEP ATP III, a
very high-risk population includes patients with a com-
binationof risk factors of coronaryheart disease and acute
coronary syndrome (ACS), and the recommended goal
for lipid lowering is <1.8 mmol/L (70 mg/dl) or a
reduction of40%.According to the Chinese guidelines,
only ACS patients and those with a combination of
ischemic CVD and diabetes belong to the very high-risk
population, and the recommended goal for lipid
lowering is <2.0 mmol/L (80 mg/dl) or a reduction of
40%. On the other hand, in the European guidelines, a
very high-risk group is defined as the population with a
SCOREvalue of>10%, or patients diagnosedwithCVD,
type 2 diabetes mellitus (T2DM), or type 1 diabetes
mellitus (T1DM), in combination with target organ
damage and moderate to severe chronic kidney disease
(CKD). The LDL-C goal for a very high-risk patient is
<1.8 mmol/L (70 mg/dl) or a reduction of 50%. TheLDL-C levels required by European guidelines for high-
risk patients with a significantly high level of individual
risk factors (5%  SCORE < 10%) and moderate-risk
patients (1%  SCORE < 5%) were <2.6 mmol/L
(100 mg/dl) and <3.0 mmol/L (115 mg/dl), respectively.
This recommended LDL-C level is more active than that
in NCEPATP III<3.4 mmol/L (130 mg/dl) and Chinese
guidelines (<3.2 mmol/L (120 mg/dl)). The latest US
guidelines causing widespread controversy proposed
abandoning the target value because currently no evi-
dence from randomized controlled clinical trials supports
reducing the lipid level to the above-mentioned target
value in clinical practice. As a result, the latest US
guideline no longer includes the LDL-C and non-HDL-C
target values in the primary and secondary prevention of
coronary heart disease. However, this guideline has
stressed that for patients with atherosclerotic cardiovas-
cular disease (ASCVD), regardless of baseline LDL-C
levels, patients <75 years old should start high-intensity
statin therapy, and high-intensity, moderate and low
statin therapies are defined according to the magnitude
of LDL-C reduction. High-intensity statin therapy is
defined as the daily dose that can reduce LDL-C level by
50%. The latest US recommendation indicates that the
major risk factors for ASCVD include: (1) age (men45
years, women 55 years old); (2) a family history of
premature coronary heart disease (male first-degree rel-
atives<55years, female first-degree relatives<65 years);
(3) smoking; (4) high blood pressure; (5) low HDL-C
level (male 40 mg/dl, female 50 mg/dl); (6) elevated
levels of non-HDL-C andLDL-C; and (7) diabetes. High-
risk and very high-risk groups include patients with (1)
ASCVD; (2) LDL-C 190 mg/dl; (3) T1DM or T2DM;
and (4) stage 3 or higher CKD. This lipid management
recommendation combines different views on whether to
retain the LDL-C target values in these guidelines, and
finally provides explicit recommendation on retaining the
LDL-C target value. The identified LDL-C target values
according to the risk stratification are the same as those in
the European guideline.
Compared with the NCEP ATP III as well as the
Chinese guideline,6,7 the European guideline continues
to affirm statins as the cornerstone in the treatment of
atherosclerosis, and more actively recommends start-
ing drug treatment for high-risk and very high-risk
groups. In NCEP ATP III and the 2007 Chinese
guidelines on prevention and treatment of dyslipidemia
in adults drug therapy will be initiated for high-risk
(coronary heart disease, stroke, diabetes, ACS) pa-
tients with an LDL-C level of >2.6 mmol/L (100 mg/
dl), and may be considered with an LDL-C level of
<2.6 mmol/L (100 mg/dl). The European guideline
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very high-risk (coronary heart disease, stroke, dia-
betes) patients with an LDL-C level of >1.8 mmol/L
(70 mg/dl), and may also be considered even if the
LDL-C level is <1.8 mmol/L (70 mg/dl). For ACS and
myocardial infarction (MI) (including acute myocar-
dial infarction and previous myocardial infarction)
patients, statin therapy should be immediately started
regardless of LDL-C levels. For the first time, the
European guideline has proposed that CKD patients
are an very high-risk group for cardiovascular disease.
Lowering LDL-C level may reduce the risk of CVD in
patients with CKD, and therefore should be recom-
mended (IIa/B). Statins are recommended to moder-
ately delay the progress of renal dysfunction, thus
preventing the development of end-stage renal disease
requiring dialysis treatment (IIa/C). Given the benefits
of statins on pathologic proteinuria (>300 mg/dl), the
use of statins should be considered for stage 2e4 CKD
patients (IIa/B). For patients with moderate to severe
CKD, the use of a statin alone or in combination with
other drugs should reduce the LDL-C level to
<1.8 mmol/L (70 mg/dl) (IIa/C), and statins that are
metabolized via the liver are preferred.
The review of evidence in the new US guideline
focuses on the cholesterol management that has the
greatest significance in lipid lowering, and suggests the
type of patients who should accept “statin” treatment,
and the intensity of statin therapy that can achieve the
precise benefit of reducing ASCVD risk. At the same
time, the new guideline uses the evidence from a
randomized clinical trial study as its basis, and pro-
poses four groups that can benefit from statins: (1)
ASCVD patients with clinical evidence; (2) patients
with primary elevation of LDL-C 190 mg/dl
(4.9 mmol/L); (3) diabetic patients aged 40e75 years
with no clinical evidence of ASCVD and an LDL-C
level of 70e189 mg/dl (1.8e4.9 mmol/L); and (4)
patients with no clinical evidence of ASCVD, or dia-
betic patients who are 40e75 years old, with an LDL-
C level of 70e189 mg/dl (1.8e4.9 mmol/L) and a 10-
year ASCVD risk of 7.5%.If a patient with ASCVD
does not have contraindications or statin-related
adverse events, he/she should receive high-intensity
statin therapy, including rosuvastatin (the recom-
mended dose: 20e40 mg) or atorvastatin (the recom-
mended dose: 80 mg), to reduce the LDL-C level by at
least 50%. For the patients with dose-related adverse
reactions, the treatment can be changed to moderate-
intensity statin therapy. The patients with an LDL-C
level of 190 mg/dl should receive high-intensity
statin treatment, to reduce the level of LDL-C by atleast 50%. The diabetic patients aged 40e75 years
with no clinical ASCVD should receive at least
moderate-intensity statin therapy, to reduce the level of
LDL-C by 30%e40%; Patients who are 40e75 years
of age with no clinical ASCVD or with diabetes and an
LDL-C level in the range of 70e189 mg/dl and a 10-
year ASCVD risk of >7.5% should receive moderate
or high-intensity statin treatment.8
Clinical considerations of “target” and “target
goal” in lipid management
In the 2013American College of Cardiology
(ACC)/American Heart Association (AHA) guideline
on the treatment of blood cholesterol, the recom-
mended target goal was abandoned, which caused
hesitation and confusion among domestic and inter-
national medical staff. The vague, recommended
strategy for “target” and specific “target goal” had
some negative effects. The 2014 NLA recommenda-
tions for dyslipidemia management retained the target
goal based on an explicit determination of “target,”
clearly reflecting the important clinical significance
of defining “target” and “target goal” in lipid-
lowering therapy. The ultimate goal of developing
guidelines is to regulate medical practice. Therefore,
a guideline must be closely combined with clinical
practice in order to properly promote and apply the
guidelines. In clinical practice, when advising specific
patients to follow medical recommendations, clini-
cians can use a patient-centered approach by per-
forming risk stratification based on the latest
recommendations for the management of dyslipide-
mia. LDL-C should be used as the primary target, the
required target value for LDL-C is determined, and
both doctors and patients should have a well-defined
target and goal. Doctors can choose appropriate and
reasonable lipid-lowering treatments, and with the
“lipid-lowering target,” patients can improve their
therapeutic compliance and level of cooperation,
thereby reducing the discontinuation of lipid-lowering
drugs due to unclear goals. As a result, the benefits
for patients with different risk levels after stratifica-
tion can be maximized for lipid-lowering treatment,
and the occurrence and development of cardiovascu-
lar events can be minimized.
Of course, it is worth noting that clinical situations
are complex, although one may understand the clinical
significance of “target” and “target goal” in lipid-
lowering therapy. In specific clinical practice, one
may encounter specific issues. For example, should
lipid-lowering therapy be continued when the patient's
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statin drugs be combined when the existing intensive
statin therapy cannot reduce the patient's LDL-C to the
target? How to deal with patients' concerns about
“excessive lowering of LDL-C level?” In the 2013
ACC/AHA guidelines on the treatment of blood
cholesterol, the reason to abandon the target value is
that a large-scale RCT cannot determine “the threshold
value of LDL-C level at which there is no reduction in
cardiovascular events.” There are potential positive
effects on clinical practice from “abandoning the
target.” For example, doctors and patients will not
easily adjust the dose of statins based on blood lipid
tests; the dose of statins will not easily be reduced for
patients whose LDL-C level reaches the target; and
non-statin drugs with no confirmed clinical benefits
will not easily be combined for patients whose LDL-C
level does not reach the target.9
Therefore, when determining the retention of
“target” and “target goal” in lipid-lowering therapy,
one should correctly apply the basic concepts of
“target” and “target goal,” to better apply the “guide-
line recommendation” in clinical practice.
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